PART ONE Rheumatoid arthritis overview; 1 Classification ofrheumatoid arthritis; References; 2 Pre- rheumatoid arthritis; What is pre-rheumatoid arthritis?; Risk factors for rheumatoid arthritis; Systemic autoimmunity associated with rheumatoid arthritis; Symptoms without clinical arthritis; Unclassified arthritis; References; 3 Early rheumatoid arthritis; Introduction; Pathology in early rheumatoid arthritis; Diagnosis of early rheumatoid arthritis; Classification of rheumatoid arthritis; Management of early rheumatoid arthritis

Recommendations for the management of early rheumatoid arthritisReferences; 4 Established rheumatoidarthritis; Introduction; Stages of established rheumatoid arthritis; Common clinical presentations; References; 5 Remission and rheumatoidarthritis ; Introduction; Defining remission; Imaging remission; Immune-mediated remission; Drug-free remission; Optimal dose reduction regimes for patients in remission; References; PART TWO Imaging of rheumatoid arthritis; 6 Magnetic resonance imaging in rheumatoid arthritis; Introduction; Technical aspects; Visualizing rheumatoid arthritis

Diagnosing rheumatoid arthritisMonitoring disease activity and structural damage; References; 7 Ultrasound imaging in rheumatoidarthritis; Introduction; Ultrasound and rheumatoid arthritis; Cartilage damage; Management of rheumatoid arthritis with ultrasound: diagnosis,therapeutic follow-up, remission, and flare; Conclusion; References; 8 Dual energy X-ray absorptiometry in rheumatoid arthritis; Introduction; Bone remodeling in rheumatoid arthritis; Bone damage imaging in rheumatoid arthritis; Treatment of bone loss in rheumatoid arthritis; References

PART THREE Treatment of rheumatoid arthritis9Methotrexate; Introduction; Historical perspective; Mechanism of action and pharmacokinetics; Dosing; Benefits; Monitoring; Side effects; References; 10 Immunotherapy; Introduction; Nonbiologic disease-modifying antirheumatic drugs; Biologic disease-modifying antirheumatic drugs; Cost-effectiveness of immunotherapy in early rheumatoid arthritis; Recommendations for the use of disease-modifying antirheumaticdrug therapies; Safety of immunotherapy; Prospective new targets for immunotherapy; References; 11 Rituximab

B-cell development and differentiationEfficacy of rituximab in rheumatoid arthritis; 12 Novel therapies in rheumatoidarthritis: small molecules; Introduction; Inhibiting intracellular signaling pathways; Conclusion; References